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Abstract
The last 6 years have seen sustained investment in health data science in the United
Kingdom and beyond, which should result in a data science community that is inclu-
sive of all stakeholders, working together to use data to benefit society through the
improvement of public health and well‐being.
However, opportunities made possible through the innovative use of data are still not
being fully realised, resulting in research inefficiencies and avoidable health harms. In
this paper, we identify the most important barriers to achieving higher productivity in
health data science. We then draw on previous research, domain expertise, and the-
ory to outline how to go about overcoming these barriers, applying our core values of
inclusivity and transparency.
We believe a step change can be achieved through meaningful stakeholder involve-
ment at every stage of research planning, design, and execution and team‐based data
science, as well as harnessing novel and secure data technologies. Applying these
values to health data science will safeguard a social licence for health data research
and ensure transparent and secure data usage for public benefit.
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1 | INTRODUCTION: HEALTH DATA
SCIENCE AS A UK NATIONAL PRIORITY
Health care and health research are being rapidly and dramatically
transformed by the increasing availability of electronic data and the
extraordinary advances in computational power required to process
them. New knowledge is being generated by significant advances in
health informatics, in data capture and curation, knowledge represen-
tation, and data analytics. These advances are critical both to the deliv-
ery of healthcare for the population of the United Kingdom (population
66.6 million) and to the digital health and life sciences sector, one of
the most dominant economic sectors in the United Kingdom, estimated
to be worth approximately £67bn in 2016.1 Because of demographic
and population pressures, there is a substantial need for greater effi-
ciency within the UK health system. In the UK National Health Service
(NHS) the Five Year Forward View and Personalised Health and Care
Plan 2020 set out a strategy for the NHS in England to revolutionise
health and care for patients through the adoption of digital tools and
technologies. Specifically, NHS Digital's Data Services Platform is seen
as the infrastructure for a future national Learning Health System.2
In March 2013, the Farr Institute of Health Informatics Research—
a collaboration of 21 academic institutions and health partners across
the United Kingdom—was established to bring about a step change in
the harnessing of data to improve population health, to address health
inequalities, and to drive efficient service provision. Farr's vision was
encapsulated by its “#datasaveslives” tagline. The Farr sat within a
growing international, interdisciplinary community of those concerned
with “population data science” (ie, the science of data about people),3
which in turn sits within the wider “Big Data” landscape of those seek-
ing to use increasingly rich digital data for a wide variety of purposes.
Since its creation, Farr researchers have successfully harnessed the
power of data to study a wide range of clinical and public health
issues. An important focus of the Farr has also been bringing together
data sets from different health‐care and administrative sources
through confidential record linkage. These datasets have included hos-
pital and primary care data, as well as public health (eg, screening
programmes) administrative and educational data. Whilst the main
focus of the Farr Institute was on quantitative data science, qualitative
work provided additional insights into public attitudes to data sci-
ence,4 into the underlying drivers and motivators of behaviours,5 and
enthnographic insights into the data science process.6 Through these
approaches, Farr researchers published 238 peer‐reviewed papers
during 2016‐2017 alone.7
However, there remains concern that the opportunities made pos-
sible through the innovative, efficient, and secure use of data are still
not being fully realised, resulting in avoidable health harms.8 Addition-
ally, attempts to broaden the range of datasets that are used within
data linkage studies have made slow progress. This includes data from
novel sources such as social network platforms, commercial transac-
tion records, smartphones and wearable devices, sensors, and
Internet‐connected devices, both in the home and the public realm.
Research has demonstrated that these data can be used to inform
improvements in population health, for example, by characterising dis-
ease outbreaks in near real time,9 identifying adverse effects of med-
ications,10 and predicting clinical deterioration after hospital
discharge.11 The United Kingdom (and England in particular) also falls
behind other countries in linkage of cross‐sectoral data to inform anal-
yses of health (eg, from employment and criminal justice systems).
In March 2017, Health Data Research UK (HDR‐UK) was
announced as the successor to the Farr Institute, and its scientific
programmes were formally launched on 1st of May 2018. The incep-
tion of HDR‐UK is an opportune time for considering priorities for
the future. In this paper, we, the members of the first cohort of Farr
“Future Leaders,” consider what the most important priorities might
be for achieving a sustainable step change in productivity in health
data science in order to enhance the health of the population.
2 | VISION: OUR DATA, OUR SOCIETY, OUR
HEALTH
Our vision is for a health data science community that is inclusive of all
stakeholders, working together to use data to benefit society through the
improvement of public health and well‐being. We want health and pop-
ulation data science to be supported by, guided by, and of direct ben-
efit to, as much of society as possible. The tagline “Our Data, Our
Society, Our Health” emphasises the role of society in delivering inclu-
sive and transparent health data science.
This new social contract rests on meaningful stakeholder involve-
ment at every stage of research planning, design, and execution,
requiring a broad range of researcher skills to ensure our infrastruc-
ture, governance, analysis, data management, information security,
and communications are all efficient, appropriate, and closely aligned
to stakeholder priorities. Our vision thus needs to be communicated
and executed in a manner that is clear, transparent, and inclusive.
We will take responsibility to ensure that the general public have
the information and opportunity to understand, engage with, and ben-
efit from the outputs of science based on their data.
3 | CURRENT BARRIERS TO ACHIEVING
OUR VISION
We perceive a number of barriers to achieving the vision of inclusive
and transparent health data science, including obstacles to data
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access, variability in data quality, current skills and capacity, and
importantly, managing of public trust in health data research.
3.1 | Data access barriers
A key issue for researchers in health data science is the risk inherent in
securing access to data. Data access can be blocked by “hard” barriers
such as restrictive legislative clauses or financial and technological
restrictions imposed by electronic medical record (EMR) vendors12
and “soft” barriers such as risk aversion to data sharing on the part
of data custodians or ethics committees. These barriers curtail
research not only through blocking access to data but also through
delaying access to data to an extent where it threatens the viability
of typical grant‐funded research or PhD projects.13
The thinking behind these barriers may be explained by prospect
theory, which is widely used in behavioural economics and identifies
loss aversion as a significant and consistent cognitive bias when
choices are made in the face of uncertainty.14 There is an overempha-
sis on perceived negative impacts of prospects that are of low proba-
bility but can involve large losses, leading to inertia. We consider that
risk aversion and subsequent inertia have resulted from data owners
responding to rare events such as data breaches15 (eg, HM Revenue
and Customs ceasing to share data following the loss of CDs contain-
ing the records of 27 m UK taxpayers16), public scandal (eg, changes in
NHS data‐sharing practise following the Partridge Review17), and leg-
islative change (particularly when there is limited regulatory guidance
on how to interpret the new legislation). Inertia and risk aversion are
also introduced where governance challenges are identified, but the
data owner is either unfamiliar with technical solutions or is not cer-
tain that these are compliant with regulations. Even the introduction
of legislation designed to facilitate data science, such as the UK imple-
mentation of the EU General Data Protection Regulations (GDPR) and
the UK Digital Economy Act 2017, lead to uncertainty and potential
harms, whilst regulators and data owners work to develop new codes
of practise and establish new norms.
Currently, data access is hampered by a lack of, or inconsistent use
of, national standards. For example, UK government departments dif-
fer in expectations as to how researchers demonstrate information
security standards, with some data owners accepting ISO27001 certi-
fication18 (arguably the leading international information security
accreditation standard), others requiring NHS Information Governance
Toolkit,19 and other departments requiring evidence of compliance
with HM Government Security Policy Framework.20 The lack of con-
sistency increases administrative burden on the research community
and makes data application processes and timescales unpredictable.
These inconsistencies again contribute to risk aversion by decision
makers who are minded to take a cautious interpretation of legislation,
are not clear what the law allows, and may lack familiarity with inno-
vative data science proposals and technologically driven solutions.
Similarly, local ethics committees may have poor knowledge of data
sharing and data science projects because of the low throughput of
these projects in their geographical area. Furthermore, some
centralised data access bodies operate in opaque ways, which are dif-
ficult for researchers to navigate and lack opportunities for meaningful
engagement.
A further inconsistency lies in differing government structures and
governance environments across the four home nations comprising
the United Kingdom. Using research access to hospital and registry
records as an example: in England, access to hospital data is obtained
through NHS Digital, with applications considered by the Independent
Group Advising on the Release of Data (IGARD); in Scotland, data can
be requested from the Information Services Division and the National
Records for Scotland, where applications are considered by the Public
Benefit and Privacy Panel for Health and Social Care (PBPP) via eDRIS;
in Wales, researchers gain access to data held in the Secure
Anonymised Information Linkage (SAIL) Databank, held at Swansea
University, through an application to an independent Information
Governance Review Panel; in Northern Ireland, decisions are ulti-
mately made by the medical director of the care organisation. There
are many settings where conducting research with data from several
jurisdictions is valuable and/or unavoidable (eg, following participants
who move to a different region in the United Kingdom or including
participants from all regions of the United Kingdom to enable investi-
gation of rare conditions or to help draw a representative national
sample), but currently, this requires multiple approvals with inconsis-
tent mechanisms.21 In addition, ethics committees and other gover-
nance groups such as the Health Research Authority Confidentiality
Advisory Group have requirements that can conflict with the data pro-
viders', eg, in wording for privacy notices in line with GDPR require-
ments. It is not currently clear which (if any) decision has primacy,
and researchers may have to provide several iterations of documenta-
tion to satisfy all parties. This barrier to efficient access to records, or
an efficient mechanism for whole population sampling, has been
recognised by the UK Economic and Social Research Council,22 who
propose a national population “spine” as part of the means to address
these inconsistencies.
The upshot of these inconsistent approaches is that whilst there is
clear support for increased use of routine data in research aiming to
improve the public good at the highest levels,23 this is not manifesting
itself in consistent and timely access to data. For example, a parlia-
mentary report from the select committee on artificial intelligence24
fears the benefits of data science to patient care could be stymied
by a lack of a consistent approach to data‐sharing arrangements
between NHS organisations and developers of artificial intelligence.
Some new data sources, for example, social media, are subject to
few restrictions or guidelines as to their appropriate use. This has
resulted in a culture of self‐governing in which researchers make
decisions about how to act ethically on a case‐by‐case basis. This
has led to misuse and scandal.25 Indeed, many publications based
on social media data do not mention ethical issues or simply state
that consent was not required because the data were available in
the public domain.26 However, this is a rapidly evolving space, and
there is increasing recognition of the need for ethical governance
structures and guidelines for research based on Internet‐
generated data.26
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3.2 | Data quality barriers
To maximise the public benefit of health data research, it is imperative
that data quality issues or biases within the data are understood and
accounted for in the analysis process. There are challenges in using
data not originally collected for research; hence, there is a large body
of literature focused on assessing the validity of routinely collected
health data.27,28 This is also now extending to validation of some inno-
vative data sources, such as sensor data.29 However, there is a rapidly
growing number of new data sources for which the limitations and
potential biases have not been identified.30,31 A particular challenge
for users of many nontraditional data sources lies in creating replicable
case or concept definitions that are critical to understanding the
extent to which the data source offers unbiased and complete infor-
mation on the topic under study.31 Linking novel data, eg, social media
data, into richly phenotyped cohort studies, with alternate sources of
exposure or outcome data, provides opportunities to test the “ground
truth” of assumptions made elsewhere solely using novel data.32
The potential for research that benefits population health is
increased exponentially with the linkage of data across multiple
sources, but a lack of unique and accurate identifiers to link data across
different sources can affect the quality of linkage.33 In turn, linkage
error can undermine the representativeness of analyses, for example,
by excluding data from hard‐to‐reach populations.34,35 In many jurisdic-
tions, separation of linkage and analysis processes is recognised as good
practice for protecting privacy.36 However, this can lead to a “black‐
box,” with researchers finding it difficult to obtain the information nec-
essary to evaluate data quality and to provide transparent reporting
that allows other researchers to reproduce and validate the research.37
3.3 | Skills, progression, and team working across
disciplines
Health data science is widely recognised as a difficult area to train in
or move into from other data domains, due to a lack of training oppor-
tunities, investment, and structured opportunities to discipline hop
from other data intensive fields. Universities often face structural
and logistical challenges that prevent them from offering effective
cross‐disciplinary postgraduate courses in the area. This has resulted
in a shortage of individuals with skills and expertise to innovate and
maximise benefits of big data in health. This situation is exacerbated
by industry demand for individuals with these skills; we recognise that
this is both a drain on university‐based research, yet also a major
driver for government investment into health data science.
The rise of the “data scientist” as a distinct role—where expertise is
centred on data and data systems, rather than aligned roles centred on
statistical, epidemiological, biological, or social science expertise—has
proved difficult to accommodate in traditional university career path-
ways. This is increasingly the case as larger research initiatives (such
as HDR‐UK substantive sites or large longitudinal studies) employ spe-
cialists to develop data linkages, build datasets, and build advanced
systems to manage the storage, sharing, and use of these data, whilst
ensuring compliance with relevant ethico‐legal requirements. Whilst
data scientists may have a traditional “academic” pathway (PhD study,
lectureship, or fellowship), they may also have more of an IT or data
administration role. Because of these hybrid academic/administrative
functions, progression routes, and metrics of success, can be unclear;
those in senior data scientist roles may not meet either traditional
research metrics (PhD, publication history, and grant income) or tradi-
tional university administration metrics (managing large teams or
budgets).
Researchers who work in cultural silos are unlikely to maximise the
potential of patient data. However, at the current time, setting up
effective cross‐disciplinary groups can be challenging, because of the
lead time of learning to “speak each other's languages,” understanding
each party's data management and analytical approaches, and aligning
aims and priorities.
3.4 | Public and patient trust
There are several important barriers in terms of gaining public trust for
researchers to access health records on a large scale. Whilst there is
good evidence that the public support the secondary use of routine
data,4 previous highly public cases (eg, care.data scheme to centralise
primary care records in England38 and Google use of Royal Free data
to develop artificial intelligence algorithms39) place this public support
and trust at risk. Furthermore, wider misuse of data (eg, the use of per-
sonal information from Facebook to target election campaigning40) and
the increasing monetisation of data and advice (eg, pharmaceutical
company donations to patient advocacy groups in the United States41),
risk reducing public trust for all complex data (re)use. Any loss of public
trust in the NHS and universities as data custodians will impact on the
ability of clinicians to deliver effective, efficient, and safe care, and the
ability of academics to access and use patient data for research.
Decision makers are currently very conservative in allowing data to
be shared or linked across different sites or trusts, because of perceived
privacy risks. As previously discussed, this may be driven by fear of neg-
ative news headlines and the large financial and reputational costs of
data breaches.42 However, there has been a notable failure to balance
this against the ethics of data non‐use: not sharing data may be actively
harmful, and costs lives, if progress in research is not made.8 Unfortu-
nately, this concept of harm through restrictive use of data barely
weighs within the current ethics discourse, and the major focus on
ethical review relates to the possible harms from privacy breaches.
Decisions about data linkage and sharing for research must balance
individual rights and societal benefit, and in each case evaluate the
risks and rewards of the particular research project, the data security
infrastructure, and societal perceptions, as depicted in Figure 1.
4 | INCLUSIVE INVOLVEMENT OF
STAKEHOLDERS
In order to deliver our vision for health data science that is inclusive of
all stakeholders, we propose new approaches for engaging with the
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public, data owners, and regulators; managing diverse and inclusive
research teams; and enabling transnational health data science.
4.1 | Engagement with the public and securing public
trust
Two key issues have been identified in relation to trust around use of
patient data: the public must trust research organisations' competence
with data handling, and must trust their motivations for data analysis.4
To facilitate that trust, we must understand the level of control
patients desire over their data, understand how to obtain and maintain
public trust, connect our efforts to individual communities, and pro-
mote the societal benefits resulting from our work in order to secure
a social licence for health data science.
Researchers can also maintain public trust and support by having a
better understanding about what level of control patients wish to have
over their data and how they wish to achieve this. At present, our
understanding of whether patients want granular control over their
data is limited, and there are several areas of work to be undertaken.
Some evidence suggests the public are most in favour of an opt‐out
system for data usage after deliberative or educational events, such
as citizens' juries where they have had the chance to explore the
issues and understand the problems of selection bias in an opt‐in
model.43 This even extends to vulnerable and marginalised groups
such as people who have experienced homelessness.44 Communica-
tion and clarity of argument is key here however, as GDPR has created
an expectation of opt‐in mechanisms, which are now required in
online and commercial contexts but not for researchers using data
for the performance of a task carried out in the public interest and
for scientific research involving sensitive (eg, all health) data.45 The
data‐science community will need to publicly articulate the need for
opt‐out approaches, demonstrate the societal benefits these bring,
and co‐design alternate safeguards (if needed) with the public.
At present, the UK public are wary of NHS data handling compe-
tence46 and many report not trusting the motivations of private sec-
tor or government organisations.47 Conversely, and perhaps
surprisingly, the public also express trust for clinical and academic
institutions to appropriately use health record data, because of pub-
lic benefit–focused motivations.48 One report investigated public
attitudes to sharing data with commercial entities and concluded that
a strong case for public benefit is the most important factor for most
people to agree to research in this context. Without it, data use by
any organisation is rarely acceptable.49 There is a recognised need
for better communication with the public about the use of health
data in private and public sector collaborations.50 It is not currently
clear what the public perceive as a “fair usage” of data for a private
technology company compared with that for the NHS, a question
that should be investigated further as a matter of urgency given
rapid developments in this field. Options may include the primary
research partnership being between the NHS and a university, and
any private company wishing to access the data would need to
approach this established collaboration as a third party and show
investment in the research within one or both of the public
organisations.
The social landscape around data sharing is rapidly evolving and
hard to predict. However, many researchers working in the field of
public engagement are operationalising the theory of social licence
to inform dissemination of plans for data‐sharing schemes. First
developed around ideas of corporate social responsibility, social
licence theory proposes that the public expect that, in some circum-
stances, the conduct of groups or organisations should go further
than the requirements of formal regulation, towards voluntary adher-
ence to social codes of trustworthy and responsible behaviour.51
Where the public are satisfied that the motivations of the organisa-
tion are trustworthy, they grant a “social licence” to operate. Securing
and maintaining public trust, and thus a social licence, for the use of
patient data for research must be present in all endeavours within
the health data science community.52 This approach has been
FIGURE 1 Influences on achieving balance
between individual privacy and societal
benefits when considering data use
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pioneered at a project level by the National Institute Health
Research's INVOLVE programme that aims to move researcher
involvement of patient/participants from engagement, through
involvement, to meaningful research codesign. Several recent initia-
tives show how this may be scaled to regional and national
programmes. The “Born in Bradford” cohort study has invested con-
siderable resource in building a sense of community around their
research (partly through the Connected Health Cities initiative). They
are reinforcing the visible benefits to the Bradford community by
moving from an observational research design to including an exper-
imental component that aims to improve service provision to families
with young children.53 The Wellcome Trust funded “Understanding
Patient Data” initiative54 has aimed to scale data use into a “national
conversation” and to improve the clarity and consistency of commu-
nications with the public regarding the use of their data and also to
tap into public altruism by producing a series of videos showing
how patients have shared their data for public benefit.
The public are often willing to share their data for the benefit of a
“community” they belong to. Community can be defined in several
ways. Firstly, as a shared geography, people feel a sense of belonging
to a place. Aiming to achieve community buy‐in this way, works well
for small countries such as Wales, or regions of England, and the
Northern Cities, as the “diameter of trust” is thought to extend to 2‐
5 million people.55 This may, however, limit community buy‐in national
English or UK research initiatives, where the population is greater than
50 million. As such, national cohort studies such as the National Sur-
vey for Health and Development, or TwinsUK, have worked on foster-
ing a community around cohort membership, rather than around a
geographical area. Secondly, a shared medical interest may foster a
sense of community interest. There have been several examples
whereby medical research charities have achieved a critical mass
amongst the patient community who support their data being used
for research into particular conditions, for example, the Multiple Scle-
rosis Register.56 We would aim to encourage a sense of responsibility
for community building by researchers, with a diverse range of stake-
holders, not only as a way of creating a greater sense of ownership of
the research by the public but also to better meet the needs of these
groups of patients.
Health researchers must actively promote the societal benefits
arising from their research, so that it becomes part of the public con-
sciousness that research using patient data results in benefits for
society. An Understanding Patient Data initiative stipulates that
researchers should routinely acknowledge their sources of data in
publications and press releases, with the view that by continually
acknowledging the use of such data, the public will see that it is being
used for the common good and thus feel more positively about its use
in general.54 To maximise public involvement, researchers should pro-
vide details of their research in open and accessible manner through
public web resources and public‐facing engagement events (eg, Pint
of Science and Cafe Scientifique). Where a sense of community has
been fostered, it will be most obvious who the key stakeholders
are, and communication can be tailored to their needs and
preferences.
4.2 | Engagement with data custodians, regulators,
and those developing data legislation
Negotiating access to data necessitates substantial engagement with
data custodians, but it is not often that researchers engage directly
with regulators setting the codes of practise or with the policy makers
who develop legislation. However, effective data science will need to
address “hard” factors, such as restrictive legislative clauses, and it is
necessary to galvanise diverse groups of stakeholders, including
patients and the public, to lobby for and facilitate legislative change.
The Wellcome Trust took this lead in galvanising the EU data science
community to press for research exemptions for onerous data protec-
tion clauses, such as the requirement for specific opt‐in for all research
use of personal data, in the recent EU GDPR. A further example is
seen in the case of the CLOSER longitudinal cohort consortium57
who worked with the Cabinet Office to develop clauses within the
Digital Economy Act58 to facilitate the sharing of routine records for
research purposes. Within teams developing legislation, it is therefore
crucial to include data scientists with an applied understanding of the
barriers faced and potential solutions and how those issues manifest
within a particular research domain.
Established facilitators who enable researchers to gain data access
also show promise in increasing efficiencies. Recently, the Economic
and Social Research Council (ESRC) have established the Administra-
tive Data Research Partnership to act as the facilitating organisation
enabling data scientists to access routine records collated by the
Office for National Statistics. Examples of further good practise and
impact in this field should be collected and made available to support
future funding for this type of activity and increasing the efficiency of
the process for comparable projects. In addition, there should be
incentives in place which encourage data custodians and providers
to manage and share data in accord with existing standards. Such open
data management incurs a financial cost, especially if security infra-
structure around it is to be maintained. Thus, going forward, it is
important that the expectation of data sharing be embedded in the
“data culture” amongst all stakeholders and financial provision be
made to enable such open data.
4.3 | The inclusive data science team
Addressing interdisciplinary and cross‐sectorial challenges within con-
temporary data science requires building teams with a diverse range of
skills and developing methods for staff retention, recognition, and
progression.
Teams, whether project‐based, institute‐based, or those working
collaboratively across institutions, are likely to require a mix of applied
investigative skills, clinical expertise, data management, governance,
and informatics expertise. This will include scientists from traditional
clinical and academic backgrounds moving between medical research,
informatics, and other disciplines. For example, astrophysicists can
have a role in transferring “big data” skills into medical informatics.59
Social scientists have important roles, as exemplified by the CLOSER
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project, linking biomedical with equivalent social studies to share best
practice and develop joint infrastructure, whilst lobbying for data
access improvements to link NHS data to cohorts.57 Sociologists help
us to understand how the general public relate to the use of their per-
sonal data and will be instrumental in generating the new governance
needed to realise societal benefit by optimising use of cohort, rou-
tinely collected, and other data more generally.60 Involving other disci-
plines widens the types of data linked to health data and increases
evidence of the impact made by social or environmental systems.
For example, geographers have worked on household‐ and
individual‐level data linkage to investigate the influence of access,
or lack thereof, to health promoting or demoting facilities.61 This is
particularly important in the hope of realising a shared responsibility
between health‐care providers, patients, and local government
who help shape local environments.62,63 Additional support will be
needed from ethicists, security experts, project managers, public rela-
tions and communications experts, and contract lawyers, amongst
others. Building such teams is challenging given the competition
between selecting in‐demand skill sets and managing these across
the project life course.
Effective mechanisms are also needed to enable retention of
skilled team members, both through direct compensation to address
the challenge of wage competition with the private sector and recog-
nition within universities that data scientists have particular value that
is often lost through the challenges of short‐term contracts and
restraints to career progression. Clear metrics are required to recog-
nise contributions from those with less “traditional” academic roles
in order to build morale and support career progression. Our recom-
mendation is that metrics are developed to establish equivalent recog-
nition between publishing well‐managed datasets to publishing journal
articles. These would need including in all key metrics reviews (eg, we
support that a “data resource” publication describing a new and valu-
able dataset should score well within the Research Excellence Frame-
work [REF]64). Assessment of research contribution at both the
individual level (eg, for promotion) and at the institutional level (eg,
in the REF) must value contributions such as setting up and managing
data security infrastructure and data resources, developing data‐
sharing policies, and engagement with stakeholders. In time, equiva-
lent measures to assess quality and impact would develop and recog-
nise good practice across the data lifecycle (i.e. from the design of data
collection tools through to the documentation and archiving of col-
lected data).
For building capacity in health data science, we propose three key
schemes. Firstly, a doctoral training programme in health informatics
and health data science is needed to generate future specialists and
leaders in the field, to be deployed into academia, industry, and the
public sector. Secondly, a professional development program aimed
at upskilling analysts and informaticians working in the NHS is needed
to deliver innovation into the health system. Thirdly, postdoctoral fel-
lowships in health data science, together with networks for early
career researchers and future research leaders, are needed to grow a
national research community. This approach has been exemplified by
The Farr Institute and taken up further by HDR‐UK.
4.4 | Enhancing the impact of health data science by
going transnational
Collaborating across international boundaries can contribute to
enhanced productivity and impact. Our proposal is for strategic
funding to support transnational research to enable meaningful and
focused collaborations. Short courses and transnational visits are
excellent means to promote knowledge exchange and seed collabora-
tive projects. Since scientific collaborations are often based on the
flow of researchers between institutions, it is important that UK's
immigration policy recognises health data science as a key area for
highly skilled migrant programmes.
The inclusion of data from multiple populations increases statistical
power, thereby improving the precision of estimates and allowing for
the investigation of relationships that could not otherwise be exam-
ined because of rare exposures, outcomes, or both. Including data
from populations with diverse genomic or social backgrounds
increases the generalisability of the research findings. Additionally,
transnational research provides opportunities to conduct “natural
experiments,” as social and environmental contexts, health infrastruc-
ture, and payment systems differ across borders.65-68
As difficulties with sharing and linking data within national bound-
aries can be magnified when attempting to scale up across interna-
tional borders, transnational research based on the inclusion of unit
record data from the United Kingdom in a centralised repository is
unlikely to be feasible in the near future. It is, however, currently fea-
sible to rapidly conduct multinational studies by applying a common
protocol or common data model across distributed networks, followed
by pooling the results. There are many successful examples of multina-
tional research arising from such distributed networks, including some
involving data from regions of the United Kingdom69-71 and a number
of EU‐funded transnational health data research projects.72-74
5 | TRANSPARENCY IN HEALTH DATA
RESEARCH
We consider transparency in the context of data flows, data process-
ing, and research outputs, proposing new approaches for governance
structures and pathways and ensuring openness of data management
and research software used.
5.1 | Transparent governance structures
Our proposal is for increased transparency of governance systems in
place for personal health data, ensuring their agility in dealing with
emerging technologies and working with patient and public groups
to create pressure to address legislative challenges.
For transparency and accountability, we must ensure that clear
information describing data flows, data‐sharing agreements, research
objectives, results, and their clinical impact are not only made publicly
available but also actively promoted. For example, researchers must
communicate the reasons why consent systems are designed in
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particular ways (eg, to reduce the impact of bias) and the safeguards in
place to control patient privacy (eg, disclosure control mechanisms),
the ethics process for accessing data, how research teams are trained
in governance, and constraints placed on data access.
Earlier, we described how ethico‐governance factors act as hard or
soft barriers to data science. Addressing governance issues is likely to
remain challenging given that governance expectations of “good prac-
tice” are dynamic, adapt to technological change, and change in social
perceptions on data use. Present‐day examples include the need to
develop frameworks to regulate and govern the use of artificial intelli-
gence in health‐care provision and also for the use of social media,
commercial transaction data, and continuous monitoring data from
sensors and “Internet of things” devices. Therefore, any given future
governance model needs to be agile, assess stakeholder expectations,
and needs to be responsive to emerging challenges.75 The feasibility of
implementing models based on frameworks such as these is
constrained by the diverging requirements imposed on researchers
by the data custodian community.
It is essential to standardise access to data through adopting coor-
dinated standards across research communities and coordinated
research infrastructure (eg, to build on the NHS's Integrated Research
Application System [IRAS] as a one‐stop‐shop for all ethics and data
applications). Flexibility should be further enhanced by separating
evaluation and accreditation of data handling for individuals and
research projects. In this scenario, a research project would still need
ethical review but would be carried out only by individuals who have
undergone training (eg, in confidentiality and disclosure control), have
valid contracts with bona fide institutions, and have achieved the
thresholds required to hold some form of “data research passport.”
This would facilitate collaborative team working across institutions
and reduce the overheads involved with setting up individual projects
and their management.
5.2 | Honest data management
Today's data science community has access to information technology
and governance solutions needed to ensure data science takes place in
an “honest” manner; that is, the assurances provided to the public and
data owners when the data was acquired and (re)used in research are
transparently upheld and auditable.
Current attempts to reduce disclosure risk often impact on the gran-
ularity of individual level data, as data are made more anonymous by
aggregation or stripping out details at the patient level. We believe a
better way to protect patient privacy but retain granularity is the Data
Safe Haven or Trusted Research Environments (TRE) approach,7,76
where data are kept in their full resolution but access is restricted to
bona fide users.75 This is illustrated by the capabilities within the SAIL
databank to conduct address level data linkage, using a novel data link-
age system containing anonymised patient address data.77,78 Data pro-
vider and societal reassurance is further secured by controls over
access (eg, researcher training, auditing, contracts, penalties, and out-
put checks). The capabilities provided by the TRE model have enabled
complex intervention and natural experiment evaluations that are
now providing valuable evidence to guide public policy governing envi-
ronment,79 education, and other large societal systems.79-81 Although
access has been a problem in the past, with unplanned outages and
restricted working hours, substantial recent investment means these
platforms are more user friendly than ever and access will likely con-
tinue to become more streamlined and more reliable.
Models for this type of socio‐technical infrastructure extend beyond
the technology needed to keep data safe whilst being used for research.
They include platform elements that promote data discovery and access
to comparable data harmonised across many studies (eg, Dementias
Platform UK). These focused research/data/clinical environments max-
imise the opportunity for data science to have rapid translational bene-
fits. Data “streams” should flow into the system, within which methods
and models sit, and are shared between experts.
For example, Connected Health Cities is a learning health system
in the north of England bringing together subject specific expertise
with data and skills analysts centred on regions,82 aiming to minimise
the “data‐action latency.” This means that insights gained from the
data should translate rapidly into action and impact in the real world.
This combination of expertise and workflow use increases the effi-
ciency of the system and hence the use of skilled individuals. An e‐
lab collates data and expertise around a scientific question or domain;
eg, STELLAR is an e‐lab/platform built around endotype discovery in
asthma using harmonised information from cohort studies and linked
routine records.83 By bringing together researchers working in a simi-
lar field, sharing their methods and data, Connected Health Cities is
able to improve the scale, replicability, and reproducibility of
their research.
Despite these promising platforms, our ability as a community to
drive methodological innovation in high‐quality data linkage is some-
times limited by restrictions on who can carry out linkage. The organi-
sations who have access to patient‐identifiable data and who act as
trusted third parties for linkage (eg, NHS Wales Informatics Service
[NWIS] in Wales, NHS Digital in England) often have limited capacity
for driving forward advances in linkage methodology. We recommend
a higher degree of integration between researchers with data skills for
developing high‐quality linkage methods and these “trusted third
parties.”84 We support data owners and data scientists working collab-
oratively (eg, recent NHS Digital workshops on enhancing infrastruc-
ture capabilities85) and suggest that senior governmental
infrastructure managers also become embedded in the data science
community (eg, the current NHS Digital Director of Data also has a
position in HDR‐UK). Where researchers have had an input to the
linkage process (following appropriate regulations), opportunities have
arisen for both in‐depth evaluation of linkage quality and methodolog-
ical advances in linkage techniques.86,87
5.3 | Reproducible software architectures
Transparency of software tooling is increasingly recognised as a
major problem in all data‐intensive settings, as the increase in
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volume and velocity of data makes it impossible to use manual
methods to track all the ways in which data is transformed and
utilised. Thus, we recommend usage of standards to specify clear
audit requirements from research tasks and usage of technologies
such as scientific workflows, to provide an auditable trail of research
data flows.
Fully transparent sharing of information between researchers
requires us to also understand data trajectories after leaving data pro-
viders.37 Health data will typically be processed in a range of ways
before the research analysis commences. Thus, we must adopt tech-
nological solutions to ensure information about data processing is cap-
tured and can feed the demand for descriptive information on quality
and provenance of data, and we must encode these demands in formal
guidelines. For example, the RECORD Statement makes a number of
recommendations for the reporting of how outcomes and exposures
are coded, the process and quality of linkage, and data preprocessing
or cleaning.27 This is particularly relevant when we bring together data
from different sources: methods used to format, link, and manage data
prior to analysis can have a large impact on results. Systematic sharing
of data‐cleaning frameworks, data management plans, and clinical
code lists pushes forward the efficiency of data science and allows
efficient validation of results in different datasets and settings.88
These metadata may also be shared in data science repositories (eg,
Dryad89), where researchers are encouraged to deposit data once
their work has been published.
A prospective view of recording the research workflow means cap-
turing and documenting data processes as they happen. Originally
developed within United Kingdom's eScience programme,90 “scientific
workflows” emerged as core entities for encapsulating analytical
knowledge and have recently led to the concept of Knowledge
Objects and the Common Workflow Language (CWL) standard.91
Workflows created by the company KNIME have been successfully
used in sharing computable phenotype definitions as part of the
eMerge project.92 Elsewhere, the CLOSER cohort consortium has
developed a metadata repository using the Data Documentation Ini-
tiative (DDI) 3.1 life‐cycle model,57 which is built on the concept of
defining metadata as the first step of the process and then using it
to drive the data lifecycle (eg, to build online surveys, to quality check
data being captured in real time, to document data files, and to popu-
late data discovery systems). Conversely, a retrospective view is ded-
icated to capturing, storing, and analysing the audit trail produced as
part of the research process. This data provenance captures causal
links between algorithms, data sets, and actors in a data science
research process (eg, taint analysis can be used to trace the effects
of an erroneous algorithm through the system); is recognised as a
key component to providing trust in the Learning Health System93;
and is supported by the W3C PROV standard.94
6 | CONCLUSIONS
Our vision for the future of Health Data Science in the United King-
dom is one in which inclusivity and transparency are key principles.
To achieve this vision, we need to bring in key stakeholders from
the earliest stages of research projects; embrace approaches that
allow collaboration between providers, linkers, and users; and
prioritise development of research methods that address the unique
challenges in appropriate use of routinely collected clinical and emerg-
ing sources of health data. International best practise should be
recognised and adopted.
Having articulated a “vision” for the contemporary data science
landscape within the United Kingdom and beyond, we discussed bar-
riers restricting our vision and proposed possible solutions. Our aim
has been to use insights and experiences from the Farr Institute to
help set and shape the agenda for UK Health Data Science over the
course of the next few years. We suggest a new approach that
prioritises engagement with the public; bases itself around effective
and well‐trained multi‐skilled teams with responsible governance at its
heart; and with sufficient data expertise to enable the transparent and
consistent capture, transformation, and use of complex and diverse
data.
We emphasise the need for inclusivity and transparency. Moving
forward, stakeholders' views need to be accommodated in our sector's
thinking and ideally represented in our work. This may be either
through direct inclusion in multi‐disciplinary, multi‐skilled teams or in
meaningful involvement mechanisms, such as patient panels with
active roles across the research lifecycle. The technological and gover-
nance frameworks we develop to support this work need input from
all stakeholders. The operations need to be transparent in terms of
data usage (to meet a governance need), data quality, and provenance
(to inform research analysts). Finally, research successes need to be
publicised in a manner accessible to the general public, widely pro-
moted, and celebrated.
By pushing for a societal acceptance that the usage of individual's
health data in research is a vital part of the future health system,
United Kingdom's emerging Health Data Science infrastructure and
stakeholder engagements will establish “Our Data, Our Society, Our
Health” as the new social contract to deliver a sustainable and seam-
less integration of clinical and research domains to improve the
nation's health and wellbeing.
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